一种新型方向调制近距离放疗技术用于前列腺癌高剂量率近距离放疗中保护尿道
本研究基于方向调制近距离放疗(DMBT)设计理念,提出一种无需移动部件、适配常用192Ir源的新型DMBT针,通过蒙特卡罗模拟和6例患者计划比较评估其降低尿道剂量的效果。结果显示该技术可降低屏蔽侧后方剂量,并在保持靶区覆盖等效的前提下降低尿道最大剂量,尤其在前列腺尖部前区。
要点
- 新型DMBT针由14G镍钛针内置铂屏蔽体及源槽构成,适配VS2000与GammaMedPlus 192Ir源。
- 距针1 cm处屏蔽侧后方剂量较无屏蔽侧降低49.6%(VS源)与39.2%(GMP源)。
- 6例患者计划中,DMBT计划在0 mm和2 mm边界下降低尿道最大剂量,同时保持V90%和D100靶区覆盖等效。
核心结论
- 新型DMBT技术为保护尿道(尤其在前列腺尖部前区)提供了一种有前景且临床可实施的解决方案,不牺牲靶区覆盖或不增加治疗时间。
研究设计与样本
- 采用GEANT4蒙特卡罗模拟代码对Varian VS2000(外径0.6 mm)和GammaMedPlus(外径0.9 mm)192Ir源进行模拟。
- 新型DMBT针概念由14G镍钛针内置铂屏蔽体构成,铂屏蔽体内含与源外径一致的单一凹槽以容纳HDR源。
- 屏蔽体最大厚度对VS源为1.1 mm,对GMP源为0.8 mm。
- 研究6例患者病例,通过将靠近尿道的两根针替换为DMBT针来创建DMBT计划,并与参考临床计划进行剂量体积直方图(DVH)规划标准比较。
主要发现
- 蒙特卡罗结果显示,使用新型DMBT针设计时,VS源(GMP源)在距针1 cm处屏蔽侧后方剂量较无屏蔽侧降低49.6%(39.2%)。
- 使用与原计划相同的DVH规划标准时,VS源(GMP源)DMBT计划在0 mm边界下将尿道最大剂量降低10.3%±5.6%(8.1%±5.0%),在2 mm边界下降低17.7%±14.2%(16.6%±13.3%)。
- DMBT计划保持V90%和D100靶区覆盖等效。
关键数值与推荐
- VS源(GMP源)在距针1 cm处屏蔽侧后方剂量较无屏蔽侧降低49.6%(39.2%)。
- VS源(GMP源)DMBT计划在0 mm边界下尿道最大剂量降低10.3%±5.6%(8.1%±5.0%)。
- VS源(GMP源)DMBT计划在2 mm边界下尿道最大剂量降低17.7%±14.2%(16.6%±13.3%)。
- DMBT计划保持V90%和D100靶区覆盖等效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Image-guided high-dose-rate (HDR) prostate brachytherapy is a safe and effective treatment option for prostate cancer patients; however, some patients still experience acute and late genitourinary (GU) toxicity. Studies have shown that urethral dose is associated with the incidence and severity of GU toxicity. Therefore, a technique that can further spare the urethra while ensuring adequate target coverage is highly desirable. Intensity modulated brachytherapy (IMBT) designs, such as rotating shield brachytherapy (RSBT), offer ideal dosimetry theoretically but are challenging to implement clinically due to the need for high precision in moving the treatment delivery mechanisms synchronized with the source loading. In this study, we propose a novel relatively easy-to-implement solution based on the direction modulated brachytherapy (DMBT) design concept, which does not involve moving parts and works effectively with the ubiquitous 192Ir source. MATERIALS AND METHODS: The popular Varian VS2000 (VS) and GammaMedPlus (GMP) 192Ir sources, with outer diameters of 0.6 mm and 0.9 mm, respectively, were simulated using the GEANT4 Monte Carlo (MC) simulation code. The novel DMBT needle concept consists of a 14-gauge nitinol needle, which houses a platinum shield inside. A single groove, consistent with the outer diameter of each source, was incorporated inside the platinum shield to accommodate the HDR source. The maximum thickness of the shield was 1.1 mm (0.8 mm) for the VS (GMP) source. To evaluate the effectiveness of the DMBT needle concept in reducing urethral dose, 6 patient cases were studied and DMBT plans were created by replacing two needles close to the urethra with the DMBT needles. The dosimetric comparisons between the DMBT and reference clinical plans were done by assessing the dose-volume histogram (DVH) planning criteria for the target coverage and organs-at-risk. RESULTS: The MC results showed that the use of the novel DMBT needle design with the VS source (GMP source) could reduce the dose by 49.6% (39.2%) at 1 cm from the needle behind the platinum shield, as compared to the unshielded side. Additionally, when using the same DVH planning criteria as the original plan, the DMBT plan with the VS (GMP) source reduced the maximum urethral dose by 10.3% ± 5.6% (8.1% ± 5.0%) and 17.7% ± 14.2% (16.6% ± 13.3%) for 0 mm and 2 mm margins, respectively, while maintaining equivalent V90% and D100 target coverage. CONCLUSION: The novel DMBT technique offers a promising clinically implementable solution for sparing urethra, particularly in pre-apical region, without compromising the target coverage or increasing treatment time.
引用
- Meftahi M, Qiu RLJ, Patel P, et al. A novel direction modulated brachytherapy technique for urethra sparing in high-dose-rate brachytherapy of prostate cancer. Radiother Oncol. 2023. PMID: 37423478. doi:10.1016/j.radonc.2023.109801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。